Targeting IgE in asthma

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 1, 2012, Pages 1-5

  Kuhl, Kristin ^a   Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

asthma; IgE; omalizumab; pathophysiology; therapy

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; STEROID; THEOPHYLLINE;

ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MAINTENANCE THERAPY; MONOTHERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; HUMANS; IMMUNOGLOBULIN E; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 83155190235     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834deebb     Document Type: Review

References (54)

1. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J Allergy Clin Immunol 2011; 128:495-505.
2. Orihara K, Dil N, Anaparti V, Moqbel R. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med 2010; 4:605-629.
3. Hanania NA. Targeting airway inflammation in asthma: current and future therapies. Chest 2008; 133:989-998. (Pubitemid 351536877)
4. Rosenwasser LJ. Mechanisms of IgE inflammation. Curr Allergy Asthma Rep 2011; 11:178-183.
5. Blink SE, Fu YX. IgE regulates T helper cell differentiation through FcgammaRIII mediated dendritic cell cytokine modulation. Cell Immunol 2010; 264:54-60.
6. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005; 11:27-34. (Pubitemid 40189248)
7. Kuhn R. Immunoglobulin E blockade in the treatment of asthma. Pharmacotherapy 2007; 27:1412-1424. (Pubitemid 47530447)
8. Singh J, Kraft M. Anti-IgE and other antibody targets in asthma. Handb Exp Pharmacol. 2008; 181:257-288.
9. Chand HS, Schuyler M, Joste N, et al. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol 2010; 125:1157-1158.
10. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459-465. (Pubitemid 40341694)
11. Roth M, Tamm M. The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann Allergy Asthma Immunol 2010; 104:152-160.
12. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration 2010; 80:534-542.
13. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64:1728-1736.
14. Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72:306-320.
15. Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010; 104:188-196.
16. Pace E, Ferraro M, Bruno A, et al. Anti-inflammatory effects of seven years treatment with omalizumab in severe uncontrolled asthmatics. Allergy 2010; 65:1495-1496.
17. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Adv Med Sci 2011 [Epub ahead of print].
18. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
19. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308. (Pubitemid 40293345)
20. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20:1088-1094. (Pubitemid 35331863)
21. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73-78. (Pubitemid 34822924)
22. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190. (Pubitemid 32735398)
23. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005-1015.
24. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573-582.
25. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638. (Pubitemid 38534897)
26. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210-1216.
27. Ohta K, Yamamoto M, Sato N, et al. One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma. Allergol Int 2010; 59:167-174.
28. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009; 14:1156-1165.
29. Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the exclusive study. Clin Respir J 2011 [Epub ahead of print].
30. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261. (Pubitemid 32776398)
31. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-717. (Pubitemid 38850345)
32. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28-35.
33. Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011; 127:398-405.
34. Brusselle G, Michils A, Louis R, et al. 'Real-life' effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009; 103:1633-1642.
35. Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180:637-641.
36. Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011; 43:45-53.
37. Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010; 105:313-319.
38. Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103:1725-1731.
39. Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010; 104:1381-1385.
40. Siergiejko Z, Swiebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin 2011; 11:2223-2228.
41. National Institutes of Health. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma: Summary report 2007. J Allergy Clin Immunol 2007; 120:S94-S138.
42. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483-1492. (Pubitemid 46850589)
43. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378-1386. (Pubitemid 38501353)
44. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39:788-797.
45. Tan RA, Corren J. Safety of omalizumab in asthma. Expert Opin Drug Saf 2011; 10:463-471.
46. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma Immunology/American College of Allergy, Asthma and Immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373-1377. (Pubitemid 350216610)
47. Buhl R, Fernandez Vidaure C, Blogg M, et al. No difference observed in the risk of malignancy in patients exposed to omalizumab compared to controls [abstract]. European Respiratory Society Annual Congress, Amsterdam 2011, P4004.
48. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009; 103:212-219.
49. Eisner M, Miller M, Chou W, et al.Omalizumab and malignancy; interim results from the EXCELS study [abstract]. Eurpean Respiratory Society Annual Congress, Amsterdam 2011; P3954.
50. Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in a patient with severe nonallergic asthma. Allergy Asthma Clin Immunol 2011; 7:9.
51. Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011; 66:671-678.
52. Harris JM, Wong DA, Kapp AV. Development of the asthma control composite outcome measure to predict omalizumab response. Ann Allergy Asthma Immunol 2011; 107:273-280.
53. Pace E, Ferraro M, Bruno A, et al. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 2011; 48:387-392.
54. Rabe KF, Calhoun WJ, Smith N, Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011; 66:1142-1151.